Latest news

• Pfizer’s Talzenna cleared for breast cancer in Europe

  Alecensa (alectinib), Novartis’ Zykadia (ceritinib), and Takeda’s Alunbrig (brigatinib).

• Pfizer gets EU nod for Tagrisso rival Vizimpro

  Roche’s Alecensa (alectinib), Novartis’ Zykadia (ceritinib), and Takeda’s Alunbrig (brigatinib).

• Pfizer claims rapid FDA nod for Lorbrena

  Lorbrena can also be used in patients who have seen disease progression on Roche’s Alecensa and Novartis’ Zykadia.

• Ocrevus surge keeps Roche smiling in Q3

  However, the performance of Ocrevus and other drugs such as HER2 breast cancer therapy Perjeta (pertuzumab) and lung cancer therapy Alecensa (alectinib) – plus a strong showing in Asia-Pacific markets led

• Roche’s Alecensa backed by China’s National Drug Administration

  of that is Swiss drug maker Roche, which today received an approval to market its lung cancer treatment Alecensa in the country. ... Alecensa is now approved in over 57 countries as a first-line treatment for ALK-positive NSCLC.